Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations

Abstract : Background From earlier studies it is known that the APOE ε2/ε3/ε4 polymorphism modulates the concentrations of cerebrospinal fluid (CSF) beta-amyloid1–42 (Aβ42) in patients with cognitive decline due to Alzheimer’s disease (AD), as well as in cognitively healthy controls. Here, in a large cohort consisting solely of cognitively healthy individuals, we aimed to evaluate how the effect of APOE on CSF Aβ42 varies by age, to understand the association between APOE and the onset of preclinical AD. Methods APOE genotype and CSF Aβ42 concentration were determined in a cohort comprising 716 cognitively healthy individuals aged 17–99 from nine different clinical research centers. Results CSF concentrations of Aβ42 were lower in APOE ε4 carriers than in noncarriers in a gene dose-dependent manner. The effect of APOE ε4 on CSF Aβ42 was age dependent. The age at which CSF Aβ42 concentrations started to decrease was estimated at 50 years in APOE ε4-negative individuals and 43 years in heterozygous APOE ε4 carriers. Homozygous APOE ε4 carriers showed a steady decline in CSF Aβ42 concentrations with increasing age throughout the examined age span. Conclusions People possessing the APOE ε4 allele start to show a decrease in CSF Aβ42 concentration almost a decade before APOE ε4 noncarriers already in early middle age. Homozygous APOE ε4 carriers might deposit Aβ42 throughout the examined age span. These results suggest that there is an APOE ε4-dependent period of early alterations in amyloid homeostasis, when amyloid slowly accumulates, that several years later, together with other downstream pathological events such as tau pathology, translates into cognitive decline.
Type de document :
Article dans une revue
Alzheimer's Research and Therapy, BioMed Central, 2017, 9, pp.87. 〈10.1186/s13195-017-0313-3〉
Liste complète des métadonnées

Littérature citée [25 références]  Voir  Masquer  Télécharger
Contributeur : Gestionnaire Hal-Upmc <>
Soumis le : lundi 6 novembre 2017 - 13:43:15
Dernière modification le : vendredi 31 août 2018 - 09:03:57


Publication financée par une institution


Distributed under a Creative Commons Paternité 4.0 International License





Ronald Lautner, Philip Insel, Tobias Skillbäck, Bob Olsson, Mikael Landén, et al.. Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations. Alzheimer's Research and Therapy, BioMed Central, 2017, 9, pp.87. 〈10.1186/s13195-017-0313-3〉. 〈hal-01629381〉



Consultations de la notice


Téléchargements de fichiers